February 10, 2013
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing
drug candidates for the prevention and treatment of cancer, announced that on Friday, February 8, 2013 John
A. Rogers has voluntarily resigned from Helix’s board of directors.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The
company is actively developing innovative products for the prevention and treatment of cancer based on its
proprietary technologies. Helix’s product development initiatives include its novel L-DOS47 new drug
candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the
Helix BioPharma Corp.
Tel: 905 841-2300